Medicure Inc.

As of June 30, 2026, Medicure Inc. carries a market capitalization of 6.99M, placing it among publicly traded companies globally. Its enterprise value stands at 6.19M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Medicure Inc.'s next confirmed earnings release is scheduled for November 25, 2026.

As of June 30, 2026, Medicure Inc. has 10.44M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.31, and the price-to-book ratio stands at 0.86.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.27 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.19M versus a market cap of 6.99M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Medicure Inc. maintains a current ratio of 0.97, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.02, indicating elevated leverage, while an interest coverage ratio of -2,292.00 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Medicure Inc. posted a negative return on equity (ROE) of -49.88, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -29.22, reflecting losses generated across the asset base. The company generates approximately 1.02M in revenue per employee across its workforce of 22.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.29 indicates how many times Medicure Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Medicure Inc. recorded 119,784.95 in income tax expense. The company reported a pretax loss of -5.13M and -5.25M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Medicure Inc.'s stock has gained approximately 295.93% over the past 52 weeks. The 50-day moving average sits at 1.81, while the 200-day moving average is 1.03.

Over the twelve months ended June 30, 2026, Medicure Inc. generated 22.60M in revenue and converted that into -5.25M in net income, yielding earnings per share of -0.51. EBITDA reached -3.23M, while operating income came in at -5.11M.

As of June 30, 2026, Medicure Inc. holds 1.29M in cash and equivalents against 490,413.68 in total debt, resulting in a net debt position of -1.29M. Total book value stands at 8.15M, with working capital of -236,751.43 providing operational flexibility.

Medicure Inc. produced -1.36M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -1.36M - equivalent to -0.13 per share.

Over the twelve months ended June 30, 2026, Medicure Inc. posted a gross margin of 38.00, reflecting its pricing power and cost economics. The operating margin of -22.62 and net profit margin of -23.23 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -19.51: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 4.32, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Medicure Inc. shareholders.

Medicure Inc.'s most recent stock split took place on November 6, 2012 with a 15:1 split ratio.

As of June 30, 2026, Medicure Inc. has an Altman Z-Score of -8.20, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.